Avecho Biotechnology Ltd has released a press release.
AVE CBD capsule passes two-year stability milestone
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- AVE adds TPM cannabinoid gummies to portfolio
- USPTO allows new TPM manufacturing patent
- Avecho licenses TPM for use in cancer drugs
- AVE commences manufacturing for Phase III trial
- Results of Entitlement Offer
Later from Avecho Biotechnology
- June 2023 Quarterly Activities Report & Appendix 4C
- Voluntary Suspension
- Avecho raises further $6M for Phase III trial
- Reinstatement to Official Quotation
- September 2023 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology